Increased urinary excretion of platelet activating factor in mice with lupus nephritis.
Platelet activating factor (PAF) is present in urine from humans and experimental animals in normal conditions. Very little is known about changes in PAF urinary excretion under pathologic conditions and no data are available about the origin of PAF in the urine. In the present study we explored the possibility that immunologic renal disease is associated with an increase in PAF urinary excretion using gas chromatography-mass spectrometry technique. To clarify the renal or extrarenal origin of urinary PAF we evaluated whether exogenously administered PAF (1-[1', 2'-3H]alkyl) is filtered through the glomerulus and excreted in the urine. The results show that: 1) urine from mice with lupus nephritis in the early phase of the disease contained amounts of PAF comparable to those excreted in normal mouse urine, 2) PAF levels increased when animals started to develop high grade proteinuria, 3) after intravenous injection of [3H] PAF in nephritic mice, a negligible amount of [3H] ether lipid, corresponding to [3H]1-alkyl -2-acyl-3-phosphocholine (alkyl-2-acyl-GPC), was recovered from the 24 h urine extract.
Macconi
D
D
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Noris
M
M
Benfenati
E
E
Quaglia
R
R
Pagliarino
G
G
Remuzzi
G
G
D000818:Animals; D008401:Gas Chromatography-Mass Spectrometry; D007668:Kidney / Q000378:metabolism*; D008180:Lupus Erythematosus, Systemic / Q000652:urine*; D008181:Lupus Nephritis / Q000652:urine*; D051379:Mice; D008817:Mice, Mutant Strains; D010972:Platelet Activating Factor / Q000652:urine*
D010972:Platelet Activating Factor